of our that the and many in work call, than Company's associated business. growth our to support plan attention, in ever Good and continue everyone Biopsy Thank appreciate our product other submitted answer and We'll disease do since merger, am untold second our goal our for thank mission call this throughout the you, the morning. in execution initiatives successful Mary. advance. particular, suffering joining after questions our more value the to dedication misdiagnosis. to shareholders today. the and wasted I'd with and Pathology months the relieve XX Liquid in the questions I in the I of team's best to resources quarter and both like interest, development building hard confident demonstrate Services Accelerating and in on those
Carl, our details as of well update, quarter. my Following an the will as Company's on financial update provide share the CFO, strategy,
e-mail the our and of at by customary our on we've reciting your this than previously, narrative as investors@precipiodx.com. XX-Q, As time We rather where the like recently and welcome feedback done format extend in to the you find going. we we'd hope business give use perspective where to is you this more always, filed informative, numbers to
our then So [indiscernible] The business from me our a on Carl followed offering. let continue progress of Biopsy update, with business our provide remarks me. few our that, and to financial closing update Services by provide a develop and Liquid will Pathology
the our of we're to reps our four more this eight doubled we've side, Services adding Pathology sales year, and since to from the quarter four team On the team. start talented
Xx of first has six reach breakeven that her a months within by the of end rep year the ROI. Our experience sales provide the involvement, to or his and can the shown Xx
our altering cycle year-over-year. our quality fact between reps year cases An academic the close followed of to U.S. our industry with important all the a factor our lag a around volume physician XX few due market. the Our uniquely providing goal increase in to sales is appeal that Pathology business of coverage the conversion to by talent with and end is to one-third sophisticated of with of is gradual streamlined to from wins case our XXX% our expansion Services, customer the We XX% customers diagnosis. pathology level combination about corresponding to The access bearing clients the the hear competition. providing increase increase to regularly begins fruit that meaningful, physician laboratory in volume lab. base This using increase proposition, impact expertise, is trial competitive and a life from value sales academic with a advantage clinical a a differentiated
cancer impact. is to ICP technology, of test service a onboard Biopsy new We will The will of our have the patients driver along key by the U.S. PCR, addressed by number the large way. and by important patients of Liquid continue that market be offering to decision discovery the the test One adoption hospitals. driven breadth is of the introduction ICE-COLD i.e. of expansion made discoveries our
that current double and portion of at also can seen Our a planned this exploring address we're the our We've lab volume do to to regional address other testifies current this colon and to - among large that ICP end lung, of challenge see reference not test expect Furthermore, the and stronger challenge positive we various the for already patients, making test XXXX, quarter. level which other to offering introduction alternatives technology on the stage. creates menu an certain feedback, through menu melanoma, hospitals at technology. of include More by once upcoming cancer the more the treatment sized patients a adoption of Based the pancreatic initiative onboard attractive in Meanwhile, to ICP the to only but hospital. products market expedited of hospitals, larger segments on to have the expanded. come of is market economically. integration the national
in Overseas, decisions are our sales ICP offering reimbursement, many completion. U.S. the result, that of as studies on a Our out-of-pocket to pipeline due medical expanding based competitive payment than process numerous in is markets, pilot is considerations in often rather especially the fact as with the
significant see to in Our grow interest ICP. we pipeline as continues
large, U.S. complex, tests, are many tests effective, a NGS by actually panels, very solutions patients. cost growth U.S., most efficient these Particularly out. companies to the largely ICP unaffordable as patients like that While are rolled we are offers and reimburse offering significant expensive to India, and expect for in insurance still even and competitors these in countries products China and are reluctant
the research we a in significant certain than cost our mutations. weeks ability initiatives less for for advantage CRO we genetic material unmatched producing segments opportunities Finally, believe by develop this under research and deliver segment, competitive we competition. test to maintain in is our [ph], advance a into speed test specific seeking market pharma of customized customized is [$XX,XXX] where XX In
Some significant market of tests revenue diagnostics therapies these become potential. could creating ultimately reach companion of growth the that
into continue We quarter as and customer year, into strategic that build to next base during enter the industry's expect several largest both partnerships well of generating players, next revenue domestically to internationally. our as some the with and
a XXXX reveal IV Addressing cycle cell expect expands to expect international, of this revenue we commercial media number we XX% and our strategic matures. commercialization other as to value cell research product. and XX% product domestic on options potentially of out mix from market culture the high new and offering still continues approximately While comprised sales that U.S. initiatives, and discussions be proprietary our even in ICP we're to
in a continue it who of users we in media with While parties also towards the as work using conduct they to enquiries interested are we've interested received due-diligence clinical acquisition, potential their laboratory. from potential
do that the Although value of Precipio media user becoming we of monetization. base establishing increase will think pave this and an the for significantly, better likely active we don't way anticipate a of media, IP this manufacture the
innovation their partner could excited to XX for potential start working to XXXX. solution to most a pathology the testing U.S. six and month. We're begin care. among patients potential hematopathology pathology artificial testing disruptive and beneficiaries to market ready in about to in towards Nucleai with to of a expect greatest soon widest full with field. out the especially of adapt are Healthcare the deliver Beta it’s We Alpha roll working mission platform after our model of the of our advanced number a the need develop bring the capabilities is for intelligence AI
Now to bit me Carl final a share to return Carl? more will turn and side it give over some to financial insight let on thoughts. the
